An ongoing phase I trial (NCT03618654) investigating the effect of metformin in combination with durvalumab for head and neck squamous cell carcinoma reported a significant decrease in FOXP3 Tregs and an increase in CD8+ cellular density in the stroma adjacent to the tumor. This evidence concerns the gene FOXP3 and neoplasm.